# Low-dose IL-2 for Treg Expansion and Tolerance (LITE)

> **NCT02949492** · PHASE4 · TERMINATED · sponsor: **King's College London** · enrollment: 6 (actual)

## Conditions studied

- Transplantation
- Liver Diseases

## Interventions

- **DRUG:** IL-2 (interleukin 2)

## Key facts

- **NCT ID:** NCT02949492
- **Lead sponsor:** King's College London
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-12
- **Primary completion:** 2019-01-31
- **Final completion:** 2019-01-31
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Safety concerns
- **Last updated:** 2019-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02949492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02949492, "Low-dose IL-2 for Treg Expansion and Tolerance (LITE)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02949492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*